Search results
Results from the WOW.Com Content Network
Download as PDF; Printable version; In other projects Appearance. ... Depo-SubQ Provera 104: Progestogen: SC: 104 mg every 3 mos Hydroxyprogesterone caproate: Proluton:
DMPA, under brand names such as Depo-Provera and Depo-SubQ Provera 104, is used in hormonal birth control as a long-lasting progestogen-only injectable contraceptive to prevent pregnancy in women. [ 38 ] [ 39 ] It is given by intramuscular or subcutaneous injection and forms a long-lasting depot , from which it is slowly released over a period ...
Medroxyprogesterone acetate (brand names Depo-Provera, Provera, Depo-subQ Provera 104) [4] – 150 mg (intramuscularly) or 104 mg (subcutaneously) every 3 months [3] Norethisterone enanthate (brand names NET EN, Noristerat, Norigest, Doryxas) [ 5 ] – 200 mg (intramuscularly) every 2 months [ 3 ]
As of November 17, 2004, the FDA has required a boxed warning on the Depo-Provera contraceptive injection, due to the risk of significant loss of bone density with long-term use. [ 8 ] In April 2005, FDA advisors requested that Pfizer place a boxed warning on their non-steroidal anti-inflammatory drug Celebrex ( celecoxib ) for cardiovascular ...
CICs are different from progestogen-only injectable contraceptives (POICs), such as depot medroxyprogesterone acetate (DMPA; brand names Depo-Provera, Depo-SubQ Provera 104) and norethisterone enantate (NETE; brand name Noristerat), which are not combined with an estrogen and are given once every two to three months instead of once a month. [2]
Depot medroxyprogesterone acetate, a birth control medication marketed under the brand name Depo-Provera; 2,2-Dimethoxy-2-phenylacetophenone, a radical initiator; N,N′-Dimethyl-1,3-propanediamine, a cross linking reagent; Dimethylol propionic acid; Des Moines Performing Arts, the organization that operates the Civic Center of Greater Des Moines
In the 2013 study the guideline recommendation is based on, [29] there was also a significant decrease of neonatal morbidity including lower rates of necrotizing enterocolitis (0 in the treatment group vs 4 in the control), intraventricular hemorrhage (4 in the treatment group compared with 8 in the control for a relative risk of 0.25), and ...
Download as PDF; Printable version; In other projects ... Provera, Depo-Provera: Oral, IM, SC: 1958: Available: ... See template. AR antagonists act by directly ...